Detalhe da pesquisa
1.
Pan-cancer efficacy and safety of anlotinib plus PD-1 inhibitor in refractory solid tumor: A single-arm, open-label, phase II trial.
Int J Cancer
; 153(4): 815-825, 2023 08 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-37155342
2.
Characteristics and Impact Factors of Renal Threshold for Glucose Excretion in Patients with Type 2 Diabetes Mellitus.
J Korean Med Sci
; 32(4): 621-627, 2017 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-28244288